Home|Journals|Articles by Year

Directory for Medical Articles

Research Article

JCDR. 2021; 12(6): 1012-1016

Comparison of efficacy of different class of anti-hypertensive drugs prescribed in patients with hypertension

Dr. Laxman Kumar,Dr. Pankaj Kumar, Dr. Awadhesh Kumar Jha.


Background:Hypertension is epidemic affecting one billion people and common risk factor
of death throughout the world. The present study compared efficacy of different class of antihypertensive
drugs prescribed in patients with hypertension.
Materials & Methods:84 cases of hypertension of both genders were divided into5 groups on
different drugs used for treatment. Group I had calcium channel blockers, group II had beta
blockers, group II had ACE inhibitors, group IV had angiotensive receptor blocker and group
V had diuretics. Parameters such as risk factors of hypertension, associated comorbidities,
assessment of blood pressure at baseline, after 15 days and 1 month was done.
Results: Out of 84 patients, males were 54 and females were 30. Common risk factors were
obesity in 24%, hyperlipidaemia in 26%, family history in 14%, smoking in 54% and
menopause in 24%. The difference was significant (P< 0.05). Associated co-morbidities were
diabetes mellitus in 52, COPD in 14, CAD in 40, hyperthyroidism in 11 and asthma in 5
cases. The difference was significant (P< 0.05). There was significant difference in systolic
and diastolic blood pressure recorded at baseline, after 15 days and 1 month in group II and
IV (P< 0.05).
Conclusion: Maximum efficacy was seen with calcium channel blocker and common risk
factors were obesity, hyperlipidaemia, family history, smoking and menopause

Key words: Hyperlipidaemia, hypertension, smokin

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.